Ovarian Cancer Clinical Trials in Boston, Massachusetts

39 studies are recruiting for ovarian cancer in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

   The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleu…

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06321484 on ClinicalTrials.gov

2. Video Education With Result Dependent dIsclosure

   The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better s…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT05225428 on ClinicalTrials.gov

3. Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

   This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, and primary peritoneal cancer. The name of the study intervention involved in this study is: -implant…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Brigham and Women's Hospital

   See if you can join NCT04701645 on ClinicalTrials.gov

4. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   19 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

5. REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

   The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Materials

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital-Cancer Center, Boston, Massachusetts

   Locations

   6 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06710548 on ClinicalTrials.gov

6. TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

   The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

   Stage

   Not phased

   Ages

   25 to 50

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   66 in total

   Run by

   University Medical Center Nijmegen

   See if you can join NCT04294927 on ClinicalTrials.gov

7. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

   Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   18 in total

   Run by

   Incyclix Bio

   See if you can join NCT05735080 on ClinicalTrials.gov

8. A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

   The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, wh…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   28 in total

   Run by

   Compugen Ltd

   See if you can join NCT06888921 on ClinicalTrials.gov

9. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

   This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   14 in total

   Run by

   858 Therapeutics, Inc.

   See if you can join NCT06395519 on ClinicalTrials.gov

10. Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

    The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04997096 on ClinicalTrials.gov

11. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    39 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

12. A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

    This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    15 in total

    Run by

    OnCusp Therapeutics, Inc.

    See if you can join NCT06234423 on ClinicalTrials.gov

13. Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

    The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, or endometriosis-related cancer.…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06677190 on ClinicalTrials.gov

14. Comprehensive Outcomes for After Cancer Health

    This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    7 in total

    Run by

    Pack Health

    See if you can join NCT05349227 on ClinicalTrials.gov